LONDON: GSK plc announced that, further to its announcement on 16 January 2024, GSK has agreed to sell 300m ordinary shares in Haleon plc at a price of 326 pence per share, raising gross proceeds of approximately £978m.
Following settlement of the placing, GSK will hold approximately 385m ordinary shares in Haleon, representing approximately 4.2% of the issued share capital of Haleon.
GSK and Pfizer Inc. (which holds a 32% stake in Haleon), have each undertaken not to dispose of any further shares in Haleon for a period of 60 days following settlement of the Placing, subject to certain customary exceptions and waiver by BofA Securities and Citigroup Global Markets Limited.
GSK to spinout Consumer Healthcare business into new company, Haleon